MFN Drug Pricing: Importing the Wrong Cure
TL;DR
Background: U.S. patients pay more than patients in other wealthy countries for the same branded prescription drugs. Supporters of most-favored-nation (MFN) pricing treat that gap as proof Americans overpay, and propose tying U.S. reimbursement to foreign prices. The idea has moved from a blocked 2020 Medicare rule into today’s trade debate. In April 2025, the U.S. Commerce Department opened a Section 232 investigation into pharmaceutical imports, with the Bureau of Industry and Security later advancing an onshoring framework that would condition tariff relief on company-specific MFN-pricing agreements.
But… The price gap does not prove overpayment in any meaningful economic sense. It reflects how other countries suppress branded-drug prices through monopsony purchasing by single-payer systems, health-technology assessments that set reimbursement below patients’ willingness to pay, and external reference pricing that turns one country’s suppressed price into another’s ceiling. Foreign governments use these tools to underpay for innovative medicines while shifting R&D costs onto U.S. patients. Pegging American reimbursement to those prices would import the distortion U.S. policy should confront.
Moreover… Pharmaceutical innovation depends on margins earned during a limited patent window. Compressing those margins lowers the expected returns that determine whether tomorrow’s medicines get developed, especially high-risk therapies for patients with few alternatives.
The better response would treat foreign price suppression as an anticompetitive trade distortion for targeted enforcement, not copy it into the U.S. market through the back door of a national-security tariff.
KEY TAKEAWAYS
Sticker Shock, Distorted Mirror
Per-drug comparisons make the United States look like a serial overpayer. U.S. prescription-drug prices average roughly 2.56 times those in comparable OECD countries, and about 3.44 times as much for branded drugs. But that narrow, highly visible slice of the market is not the whole thing.
Generics account for roughly 90% of U.S. prescriptions, and U.S. generic prices are the lowest among peer countries. Weighted by real-world prescribing volume, rather than the highest-priced branded drugs, net Medicare and Medicaid prescription costs run about 18% below those in Germany, France, the United Kingdom, Canada, and Japan.
The aggregate mismatch is stark. In 2022, the United States accounted for roughly half of worldwide prescription-drug revenue, but only about 13% of volume across countries. Among OECD countries, it generated about 60% of revenue on 24% of volume. American consumers generate more than 70% of OECD pharmaceutical profits, even though the United States accounts for about 34% of OECD gross domestic product.
The Cure Gets Pricier to Invent
Drug development has high fixed costs, but low marginal costs. Bringing a new molecule to market costs billions, and more than 90% of candidates fail. Once a drug wins approval, each additional dose costs relatively little to produce.
So the patent-protected window matters. Prices during that period finance the entire research portfolio, including the many candidates that never reach patients. A price control does not merely shift surplus from producers to consumers. It weakens the signal that tells firms whether high-risk, long-horizon research is worth undertaking.
Studies using demographic shifts and regional variation find that innovation responds strongly to expected revenue, with U.S. innovation tracking expected revenue at an elasticity of roughly 0.43. Given a projected $0.5 trillion to $1 trillion revenue reduction under negotiation-style proposals, those elasticities imply meaningfully fewer new drugs.
Medicare price cuts for durable medical equipment offer the cleanest natural experiment because they share drugs’ relevant cost structure. Where reimbursement fell by an average of 61%, more-exposed manufacturers cut R&D spending by 53%. U.S. patents fell 75%, device submissions fell 25%, and revenue declined 44%. New entry dropped by 49%, driven by a 90% collapse in entry by U.S. manufacturers. Outsourcing to foreign producers rose by 28%, and adverse-event rates climbed as production moved offshore.
Because price caps hit the most successful products, they truncate the right tail of returns that finances the rest of the portfolio. Frontier therapies get squeezed first. The same mechanism cuts against Section 232’s premise: Compressing margins can shrink innovation, push manufacturing abroad, and weaken the supply-chain resilience the investigation is supposed to protect.
The Ratchet Wrench
Even for those who think U.S. branded-drug prices should fall, an MFN policy is a lousy tool. MFN pricing and external reference pricing spread the lowest administratively set price across markets. If the price a manufacturer accepts in a small country becomes the ceiling in larger ones, the manufacturer may delay launches, skip markets, or hide the real price in confidential rebates. Those responses already cluster in heavily referenced countries. A U.S. MFN policy would magnify them, with foreign patients often paying the price.
In its 2020 Medicare rule, later enjoined and withdrawn, CMS acknowledged that some patients could lose access to existing providers and face longer travel, lower-efficacy alternatives, or delayed and forgone treatment. Evidence from the Inflation Reduction Act’s “maximum fair price” program, which relies on similar administered-price mechanics, shows post-enactment declines in small-molecule oncology trials, consistent with the law’s price-setting timeline.
Don’t Import the Disease
The Section 232 inquiry identifies a real problem: Foreign pricing institutions suppress U.S. returns, shift R&D costs onto U.S. purchasers, and discourage domestic production. One answer would be to treat qualifying foreign systems as anticompetitive market distortions: government interventions that weaken competition and distort price formation without an overriding public-policy justification, while giving favored interests an artificial advantage.
The right remedy is targeted, distortion-calibrated tariffication, not broad sectoral tariffs or domestic price imitation. A tariff should target the specific institutions producing the harm and should be bounded by the measured distortion rather than set for blunt deterrence. The Office of the U.S. Trade Representative could pursue targeted enforcement and negotiations aimed at transparency, nondiscrimination, and a more proportionate foreign contribution to global pharmaceutical research and development.
The United States should confront foreign price suppression, not import it. A policy that copies foreign price controls may look like hard bargaining. In practice, it would weaken the innovation base, disadvantage future patients, and mistake the symptom for the disease.
For more on this topic, see the ICLE issue brief “Don’t Import the Distortion: Why MFN Drug Pricing Would Weaken U.S. Innovation” by Kristian Stout.